TrialNature communications2026

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.

Junzhe Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.